[Retracted] Amodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes

Table 2

Crude and PCR adjusted days 14 and 28 treatment outcomes of study participants on AS/AQ or AL.

Efficacy outcome	AS/AQ		AL
	𝑁	%	𝑁	%
Crude day 14 cure rates	68		69
ACPR	61	89.7	67	97.1
ETF	02	02.9	0	0
LCF	01	01.5	0	0
LPF	04	06.0	02	03.0
Crude day 28 cure rates	61		64
ACPR	54	88.5	62	96.9
ETF	02	03.3	0	0
LCF	01	01.6	0	0
LPF	04	06.6	02	03.1
PCR corrected day 28 cure rates	56		62
ACPR	54	96.4	62	100
ETF	02	03.6	0	0
LCF	0	0	0	0
LPF	0	0	0	0

Note: Reinfections were excluded from the analysis after profiling pretreatment and recurrent parasites based on the polymorphic Plasmodium falciparum  msp  2 antigen. ACPR: adequate clinical parasitological response, ETF: early treatment failure, LCF: late clinical failure, LPF: late parasitological failure, and CI: confidence interval. Early treatment failures were noted in two patients randomized to receive ASAQ coblister. It was unclear if this was due to poor drug absorption or real treatment failures.